| Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab (NCT05267054) | BeiGene | 2022-04-25 |
| Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study (NCT04890236) | Emory University | 2022-01-13 |
| Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (NCT05052528) | University of California, Davis | 2021-09-17 |
| Copanlisib Plus Venetoclax in R/R DLBCL (NCT04572763) | Dana-Farber Cancer Institute | 2021-09-08 |
| Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib (NCT05068440) | BeiGene | 2021-08-11 |
| Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy (NCT05075603) | NeoImmuneTech | 2021-07-29 |
| CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL (NCT04995536) | City of Hope Medical Center | 2021-07-27 |
| DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (NCT04920617) | ImmunoVaccine Technologies, Inc. (IMV Inc.) | 2021-06-18 |
| A Phase I/II Study of Diffuse Large B-cell Lymphoma (NCT04856137) | National Health Research Institutes, Taiwan | 2021-05-01 |
| Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL) (NCT04833114) | GWT-TUD GmbH | 2021-04-30 |
| Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (NCT04665765) | City of Hope Medical Center | 2021-01-18 |
| Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL (NCT04659434) | Qian Wenbin | 2020-12-10 |
| Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies (NCT03272633) | Rutgers, The State University of New Jersey | 2020-10-26 |
| Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (NCT04384484) | ADC Therapeutics S.A. | 2020-09-16 |
| Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma (NCT04432506) | M.D. Anderson Cancer Center | 2020-07-27 |
| Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies (NCT04205409) | University of Washington | 2020-06-05 |
| Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (NCT04285268) | Rutgers, The State University of New Jersey | 2020-05-06 |
| Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy (NCT04409314) | University of California, San Francisco | 2020-04-16 |
| Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy (NCT04870853) | M.D. Anderson Cancer Center | 2020-04-02 |
| Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma (NCT04156828) | University of Washington | 2020-03-31 |
| Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma (NCT04205838) | Jonsson Comprehensive Cancer Center | 2020-03-04 |
| Secondary Prognostic Index in RefrActory Lymphoma (NCT04804865) | Weprom | 2020-01-01 |
| Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma (NCT03484819) | National Cancer Institute (NCI) | 2019-12-13 |
| Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma (NCT03892044) | David Bond, MD | 2019-11-05 |
| CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma (NCT03579927) | M.D. Anderson Cancer Center | 2019-10-03 |
| Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas (NCT03038672) | National Cancer Institute (NCI) | 2018-12-21 |
| A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma (NCT03688152) | Incyte Corporation | 2018-12-03 |
| Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (NCT03309878) | National Cancer Institute (NCI) | 2018-10-24 |
| Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma (NCT03321643) | National Cancer Institute (NCI) | 2018-09-18 |
| Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma (NCT03583424) | Ohio State University Comprehensive Cancer Center | 2018-09-10 |
| PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma (NCT03488251) | Molecular Templates, Inc. | 2018-08-20 |
| Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma (NCT03558750) | Vanderbilt-Ingram Cancer Center | 2018-06-14 |
| Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL (NCT03305445) | Icahn School of Medicine at Mount Sinai | 2018-05-14 |
| Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy (NCT03422523) | University Hospital Southampton NHS Foundation Trust | 2018-05-09 |
| Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma (NCT03479268) | City of Hope Medical Center | 2018-04-27 |
| Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma (NCT03440567) | City of Hope Medical Center | 2018-04-02 |
| Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma (NCT03401853) | University of Washington | 2018-03-23 |
| Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (NCT03418038) | Mayo Clinic | 2018-03-23 |
| A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas (NCT03277729) | Fred Hutchinson Cancer Center | 2017-12-05 |
| huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia (NCT03103971) | Fred Hutchinson Cancer Center | 2017-11-03 |
| Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma (NCT03019640) | M.D. Anderson Cancer Center | 2017-10-10 |
| A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (NCT03136497) | Hackensack Meridian Health | 2017-09-05 |
| Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. (NCT03150329) | City of Hope Medical Center | 2017-07-18 |
| Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05) (NCT02658968) | Nordic Nanovector | 2017-03-02 |
| Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NCT02992522) | Beth Christian | 2017-02-21 |
| Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NCT02950220) | Kami Maddocks | 2017-01-12 |
| A Phase 1 Study Evaluating Safety and Efficacy of C-CAR011 Treatment in DLBCL Subjects (NCT02976857) | Shanghai AbelZeta Ltd. | 2016-12-01 |
| JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NCT02706405) | Fred Hutchinson Cancer Center | 2016-11-15 |
| Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma (NCT02568553) | National Cancer Institute (NCI) | 2016-11-15 |
| TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (NCT02874404) | University of Nebraska | 2016-10-07 |
| Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (NCT02926833) | Kite, A Gilead Company | 2016-09-29 |
| R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (NCT02628405) | Academic and Community Cancer Research United | 2016-05-20 |
| Tumor-Specific Clonotype, Metabolic Profile, and PET/CT in Predicting Chemotherapy Response in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (NCT02405078) | M.D. Anderson Cancer Center | 2015-10-13 |
| BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL (NCT02366663) | City of Hope Medical Center | 2015-01-01 |
| Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (NCT02219737) | National Cancer Institute (NCI) | 2014-09-12 |
| Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma (NCT02051257) | City of Hope Medical Center | 2014-06-19 |
| Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma (NCT01959698) | Roswell Park Cancer Institute | 2014-04-17 |
| Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (NCT02077166) | Pharmacyclics LLC. | 2014-03-13 |
| Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (NCT01955499) | National Cancer Institute (NCI) | 2013-09-24 |
| Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas (NCT01897012) | National Cancer Institute (NCI) | 2013-07-17 |
| Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia (NCT01865617) | Fred Hutchinson Cancer Center | 2013-05-22 |
| High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma (NCT01434472) | Fred Hutchinson Cancer Center | 2011-11-16 |
| Ruxolitinib Phosphate to Treat Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Stem Cell Transplant (NCT01431209) | University of Nebraska | 2011-08-12 |